WT1 and interferon-β-vitamin D association in MS: a longitudinal study.

Area of Science:

• Neuroimmunology
• Genetics
• Endocrinology

Background:

• Polymorphisms in the Wilms Tumor 1 (WT1) gene are hypothesized to influence interferon-beta (IFN-β) treatment efficacy in multiple sclerosis (MS).
• This influence may occur through WT1's regulation of the interplay between IFN-β and vitamin D levels.

Purpose of the Study:

• To investigate whether WT1 gene variations modulate the relationship between IFN-β treatment and serum 25-hydroxyvitamin D levels.
• To conduct a longitudinal study with repeated vitamin D measurements before and after initiating IFN-β therapy in MS patients.

Main Methods:

• A prospective study involving 85 patients with relapsing-remitting MS.
• Repeated measurements of 25-hydroxyvitamin D at multiple time points (months 0, 1, 3, 6, 7, 9, 12, 18, 24).
• Patients initiated IFN-β treatment at month 6, with no prior immunomodulatory treatment.

Main Results:

• Seasonally adjusted 25-hydroxyvitamin D levels showed a slight increase after IFN-β initiation (3.1 ± 1.2 nmol/l, P = 0.008).
• The association between IFN-β treatment and 25-hydroxyvitamin D levels was consistent across patients with or without specific WT1 single nucleotide polymorphisms (SNPs) (rs10767935 and rs5030244).

Conclusions:

• This study did not find evidence that genetic variations in the WT1 gene regulate the relationship between IFN-β treatment and serum 25-hydroxyvitamin D levels in MS patients.
• The findings suggest WT1 genotype does not play a significant role in this specific interaction during IFN-β therapy.